Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? III. Antagonist's viewpoint.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003645:Death, Sudden; D004280:Dobutamine / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D020105:Milrinone; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D002316:Cardiotonic Agents; D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; D004280:Dobutamine; D020105:Milrinone